Non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene is treated with ALK tyrosine kinase inhibitors (TKIs), but is successful for only a limited amount of time; most cases relapse due to the development of drug resistance. Here we show that a vaccine against ALK induced a strong and specific immune response that both prophylactically and therapeutically impaired the growth of ALK-positive lung tumors in mouse models. The ALK vaccine was efficacious also in combination with ALK TKI treatment and significantly delayed tumor relapses after TKI suspension. We found that lung tumors containing ALK rearrangements 
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide. In recent years, the identification of key genetic alterations in non-small-cell lung cancer (NSCLC) has prompted the use of rationally targeted therapies, which showed unprecedented clinical benefits (1, 2) . Approximately 5-6% of NSCLC have chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene that generate different chimeric proteins, such as EML4-ALK, TFG-ALK, and KIF5b-ALK (3) (4) (5) . In all such fusions, constitutively active ALK acts as a potent tumorigenic driver that activates downstream oncogenic signals, leading to increased cell proliferation and survival (4) .
Experimental and clinical data show that ALK-rearranged NSCLCs respond to treatment with specific tyrosine kinase inhibitors (TKIs), such as crizotinib (6, 7) . Despite a high rate of initial response, the development of resistance to crizotinib almost invariably leads to tumor relapse and eventually to the patient's death (8, 9) . Next-generation ALK TKIs, such as ceritinib and alectinib, have been developed to overcome crizotinib resistance and can further extend survival in crizotinib-resistant patients (10) (11) (12) . Resistance to ALK TKIs is mediated by point mutations of the ALK kinase domain, by ALK gene amplification, or by activation of other compensatory pathways, so-called bypass tracks, such as EGFR, c-KIT, c-MET, and IGF-R1 (8, (13) (14) (15) (16) . Thus, additional therapies to be combined with ALK TKIs are needed to further prolong remission or clinical response in NSCLC patients with ALK rearrangements.
Immunotherapy aimed at enhancing the immune response against tumor cells shows promising efficacy in a fraction of NSCLC (17, 18) . In this context, the ALK protein has many features of an ideal tumor oncoantigen that can be exploited to design specific immunotherapies, such as a cancer vaccine. ALK is required for tumor survival and growth and expressed minimally in some nervous system cells (4, 19) . ALK is also antigenic in humans, as lymphoma patients with ALK rearrangements mount spontaneous B-and T-cell responses against the ALK protein, with measurable antibodies (20), cytotoxic T lymphocytes (CTLs), and CD4 + T helper effectors to ALK epitopes (21-24). A robust immune response to ALK is associated with a decreased risk of relapse in lymphoma patients (25). Our previous ALK vaccine in pre-clinical mouse models of lymphoma containing ALK rearrangements induced specific and potent immune responses that provided strong and durable tumor protection (19).
We here test the efficacy of ALK vaccination in lung cancer. Grafted or primary mouse models of ALK-positive lung tumors demonstrated that an ALK vaccine elicited a strong, ALK-specific CTL response in both mouse models, efficiently blocking tumor growth.
Materials and Methods

Cell Lines and Reagents.
Human ALK-rearranged NSCLC cell lines, H2228 (variant 3, E6;A20), DFCI032 and H3122 (variant 1, E13;A20) were obtained from the ATCC collection and were passaged for fewer than 6 months after receipt and resuscitation. These cell lines were further internally tested for the presence of EML-ALK rearrangement. The murine ASB-XIV cell line was purchased from Cell Lines Service (CLS) and was passaged for fewer than 6 months after receipt and resuscitation.
ALK TKIs, NVP-TAE684 was purchased from Axon Medchem and crizotinib (PF-02341066) was kindly gifted by Pfizer. LSL/G12V and Tg EGFR   L858R , as previously published (26,27), and BALB/c mice (Charles River). Mice were handled and treated in accordance with European Community guidelines.
Mice. Strains of mice used in this study include K-Ras
described in Supplementary Materials and Methods.
DNA Vaccination and
In Vivo Cytotoxicity Assay. For DNA vaccination, 50 µg of pDEST or pDEST-ALK plasmids were used as previously described (19). The In Vivo
Cytotoxicity Assay was previously reported(19).
Antibody dosing for in vivo treatment
For CD4 + and CD8 + cell depletion, anti-CD4 (clone GK1.5) and anti-CD8 (clone 2.43)
antibodies were purchased from BioXcell. For depletion mice were injected i.p. with 100µg of anti-CD4 or anti-CD8 at day -1, +5, +15 and +25. (Fig. 1C) .
ALK vaccine induced a strong ALK-specific immune response as measured by an in vivo cytotoxic assay (19) (Fig. 1D ). Ten days after the second vaccination, we injected EML4-ALK or GFP ASB-XIV cells. GFP ASB-XIV cells gave equal numbers of tumors in mice vaccinated with either a control or the ALK plasmid (Fig. 1E) . In contrast, tumors of EML4-ALK ASB-XIV cells had impaired growth in ALK vaccinated mice (Fig. 1F) . Thus, ALK vaccination induced an ALK-specific immune response that efficiently prevented the growth of ALK-positive lung tumors.
ALK vaccination delays tumor growth and increases the overall survival of EML4-
ALK-rearranged NSCLC Tg mice.
To test the efficacy of the ALK vaccine as a therapy for primary lung tumors, we generated Fig. S1L ).
To test the efficacy of the ALK vaccine, we screened ALK mice by MRI to stratify them according to their tumor burden. ALK mice were vaccinated at 4 weeks of age, when tumors were detectable in the lungs ( Supplementary Fig. S1 , H and I), according to the protocol in Fig. 2A . The ALK vaccine generated strong ALK-specific cytotoxic activity in both ALK models, comparable to WT littermates ( Immunosuppressive lung microenvironment in ALK-rearranged lung cancer.
We showed that the ALK vaccine stimulates a potent immune response against ALKrearranged lung tumors. However, the ALK vaccine did not cure the mice, which died after a delay in tumor growth ( and TIM-3 in higher amounts ( Supplementary Fig. S3E ). In addition, Foxp3 + T reg cells were also increased in EML4-ALK mice over time ( Supplementary Fig. S3F ). These data suggest that tumor lungs bearing EML4-ALK develop an immunosuppressive microenvironment reminiscent of that seen in EGFR-driven lung cancer models (34).
We also characterized the immune microenvironment in human ALK-rearranged NSCLC.
NSCLC patients with ALK rearrangements had lower percentages of CD3 S5B ). To determine whether ALK oncogenic activity directly controlled PD-L1 expression in NSCLC, we treated three ALK-rearranged NSCLC cell lines (H3122, H2228 and DFCI032) with crizotinib to inhibit ALK activity ( Fig. 5A and Supplementary Fig. S5C ).
Expression of PD-L1 was detectable in all ALK-rearranged cell lines tested and was reduced upon ALK inhibition in all three cell lines ( Fig. 5B and Supplementary Fig. S5D ).
Consistently, also PD-L1 mRNA was down-regulated ( Fig. 5C and Supplementary Fig.   S5E ). To further confirm that PD-L1 expression was driven by ALK activity, and to exclude that PD-L1 down-regulation was mediated by crizotinib inhibition of MET, ROS1, or other off-targets, we knocked down EML4-ALK by a doxycycline inducible shRNA system (16).
Again, PD-L1 expression was down-regulated upon EML4-ALK knock-down ( Supplementary Fig. S5 , F and G). We conclude that in ALK-rearranged NSCLC, PD-L1 mRNA and protein was regulated by ALK activity. Another group has recently confirmed these findings (35).
The expression of PD-L1 of the surface of tumor cells impairs anti-tumor activity of the immune system (36). We investigated whether the efficacy of the ALK vaccine could be diminished by the expression of PD-L1 on the surface of the target lung tumor cells.
EML4-ALK mice express moderate, but detectable PD-L1, and we observed similar intensity of expression by flow cytometry in EML4-ALK ASB-XIV (Fig. 5D ). We reasoned that ALK vaccine efficacy could be hampered when target tumor cells express more PD-L1.
We engineered EML4-ALK ASB-XIV cells to express more PD-L1 than parental cells by transduction with a lentivirus containing a murine PD-L1 construct (Fig. 5D ). Vaccinated mice were injected with control EML4-ALK ASB-XIV cells or EML4-ALK ASB-XIV cells expressing high PD-L1. In presence of high PD-L1 expression, the ALK vaccine was less effective in preventing lung tumor growth (Fig. 5E) , suggesting that the function of ALKspecific T eff cells was modulated by the amount of PD-L1 on the surface of target lung tumor cells.
To test whether administration of antibody to PD-1 could restore a full efficacy of the ALK vaccine, we treated mice with anti-PD-1 or control IgG (Supplementary Fig. S6A ). The treatment with anti-PD-1 alone, as well as control IgG, did not have significant effect on tumor growth and mice developed tumors comparable to controls. In contrast, anti-PD-1 treatment almost completely restored the efficacy of the ALK vaccine (Fig. 5F ). These results are consistent with findings that immune checkpoint therapy restores an adaptive immune response best in patients with high PD-L1 expression (37,38).
To show that blockade of the PD-L1/PD-1 immune checkpoint was effective with physiological expression of PD-L1, we tested anti-PD-1 treatment in EML4-ALK mice (Supplementary Figure S6B) . We observed a stabilization of tumors immediately at the end of treatment (Fig. 5G) followed by a slower growth rate as compared to control mice (Fig. 5H ). These data suggest that immune checkpoint blockade therapy could be efficacious in the physiological tumor microenvironment of ALK-rearranged lung tumors.
ALK vaccination is effective in combination with ALK TKIs.
Crizotinib treatment of NSCLC patients with ALK rearrangements has had success in clinical trials, supporting the use of ALK TKIs as main therapy for NSCLC (39). A combination of ALK TKIs with the ALK vaccine could be an attractive therapeutic possibility for NSCLC patients. In this context, ALK TKIs could reduce the tumor burden to facilitate the activity of the ALK vaccine. We tested this combination in our ALK mouse models. ALK mice were treated with crizotinib (PF-02341066) for 2 weeks (100mg/kg) and concurrently vaccinated with the ALK or control vaccine (Fig. 6A) . The immune response elicited by the vaccine was not affected by administration of crizotinib, as an equally strong ALK-specific cytotoxic immune response in vivo was also detected in ALK-vaccinated mice treated with crizotinib (Fig. 6B) . As expected, treatment with crizotinib induced the regression of tumors in both groups within 2 weeks (Fig. 6C , left and central panels, and 6D). At 6 weeks from treatment suspension, tumors relapsed at the same sites in crizotinib treated mice (Fig. 6C, top right panels) , while the combination of crizotinib and ALK vaccine delayed tumor recurrence (Fig. 6C, bottom right -E) . Therefore, the ALK vaccine is not only efficacious against the EML4-ALK WT but also against some of the most common EML4-ALK mutants that develop in patients during treatment with crizotinib or ceritinib.
Discussion
In this work we extended our previous findings on the efficacy of a DNA ALK vaccine against ALK-positive lymphoma to ALK-rearranged lung cancers. Compared to our previous work, we showed that the ALK vaccine is active not only in tumor grafts but also in primary ALK-rearranged NSCLC. Because the SP-C promoter is active since embryonic development (42), these mice are likely tolerant to human ALK. Thus, an important advance from this work is the demonstration that an ALK vaccine can overcome tolerance in mice.
In addition, we showed that the ALK vaccine could be combined with either ALK TKI treatment or the anti-PD-1 antibody. These combinatorial therapies make the ALK vaccine attractive for potential clinical use. Current therapies for ALK-rearranged NSCLC, based on crizotinib or next-generation ALK TKIs, achieve a clinical response by arresting tumor progression or inducing tumor regression. However, all patients eventually relapse and die due to development of TKI resistance (11, 43) .
In this work, we set the stage for the application of an ALK vaccine to further extend Fig. S8C ) and decreased anti-tumor activity ( Supplementary Fig.S2D ). In these settings, T reg depletion by an antibody to CD25 could partially restore the impaired cytotoxic activity generated by the ALK vaccine ( Supplementary Fig. S8C ), indicating that T reg cells could also play a critical role in the immunosuppressive tumor environment seen in ALK-rearranged lung tumors.
Similarly, the restoration of the ALK vaccine efficacy by administration of antibody to PD-1 in high-PD-L1 EML4-ALK ASB-XIV xenografts (Fig. 5) suggests that blockade of immune checkpoint molecules could powerfully potentiate the ALK vaccine.
Overall, these data suggest that combination therapy of ALK TKIs and ALK vaccine could 
